Literature DB >> 24804171

Prediction of hepatocellular carcinoma incidence risk by ultrasound elastography.

M Kudo1.   

Abstract

Entities:  

Year:  2014        PMID： 24804171      PMCID： PMC3995376          DOI： 10.1159/000343859

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  12 in total

1.  An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.

Authors:  P Bedossa; T Poynard
Journal:  Hepatology       Date:  1996-08       Impact factor: 17.425

2.  Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.

Authors:  Y Shiratori; F Imazeki; M Moriyama; M Yano; Y Arakawa; O Yokosuka; T Kuroki; S Nishiguchi; M Sata; G Yamada; S Fujiyama; H Yoshida; M Omata
Journal:  Ann Intern Med       Date:  2000-04-04       Impact factor: 25.391

3.  Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan).

Authors:  Kyu Sik Jung; Seung Up Kim; Sang Hoon Ahn; Young Nyun Park; Do Young Kim; Jun Yong Park; Chae Yoon Chon; Eun Hee Choi; Kwang-Hyub Han
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

4.  Decompensated chronic heart failure: increased liver stiffness measured by means of transient elastography.

Authors:  Agostino Colli; Pietro Pozzoni; Alessandra Berzuini; Alessandro Gerosa; Cristina Canovi; Edoardo Ennio Molteni; Marco Barbarini; Ferruccio Bonino; Daniele Prati
Journal:  Radiology       Date:  2010-10-08       Impact factor: 11.105

5.  Acute viral hepatitis increases liver stiffness values measured by transient elastography.

Authors:  Umberto Arena; Francesco Vizzutti; Giampaolo Corti; Silvia Ambu; Cristina Stasi; Silvia Bresci; Stefania Moscarella; Vieri Boddi; Antonio Petrarca; Giacomo Laffi; Fabio Marra; Massimo Pinzani
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

6.  Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage.

Authors:  Abdurrahman Sagir; Andreas Erhardt; Marcus Schmitt; Dieter Häussinger
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

7.  Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography.

Authors:  Ryota Masuzaki; Ryosuke Tateishi; Haruhiko Yoshida; Eriko Goto; Takahisa Sato; Takamasa Ohki; Jun Imamura; Tadashi Goto; Fumihiko Kanai; Naoya Kato; Hitoshi Ikeda; Shuichiro Shiina; Takao Kawabe; Masao Omata
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

8.  Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis.

Authors:  Gunda Millonig; Frank M Reimann; Stephanie Friedrich; Hamidreza Fonouni; Arianeb Mehrabi; Markus W Büchler; Helmut Karl Seitz; Sebastian Mueller
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

Review 9.  Performance of transient elastography for the staging of liver fibrosis: a meta-analysis.

Authors:  Mireen Friedrich-Rust; Mei-Fang Ong; Swantje Martens; Christoph Sarrazin; Joerg Bojunga; Stefan Zeuzem; Eva Herrmann
Journal:  Gastroenterology       Date:  2008-01-18       Impact factor: 22.682

10.  Sampling variability of liver fibrosis in chronic hepatitis C.

Authors:  Pierre Bedossa; Delphine Dargère; Valerie Paradis
Journal:  Hepatology       Date:  2003-12       Impact factor: 17.425
View more
  2 in total

1.  Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.

Authors:  Kazuko Sakai; Haruhiko Takeda; Norihiro Nishijima; Etsuro Orito; Kouji Joko; Yasushi Uchida; Namiki Izumi; Kazuto Nishio; Yukio Osaki
Journal:  Oncotarget       Date:  2015-08-28

2.  Combinational elastography for assessment of liver fibrosis in patients with liver injury.

Authors:  Tomotaka Yazaki; Hiroshi Tobita; Shuichi Sato; Tatsuya Miyake; Masatoshi Kataoka; Shunji Ishihara
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.